128 related articles for article (PubMed ID: 17163840)
21. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.
Suster S; Moran CA
Adv Anat Pathol; 2006 Nov; 13(6):316-29. PubMed ID: 17075297
[TBL] [Abstract][Full Text] [Related]
22. Manual and automated AgNOR count in differentiating reactive mesothelial from metastatic malignant cells in serous effusions.
Mohanty SK; Dey P; Rana P
Anal Quant Cytol Histol; 2003 Oct; 25(5):273-6. PubMed ID: 14603724
[TBL] [Abstract][Full Text] [Related]
23. The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
Betta PG
Monaldi Arch Chest Dis; 1998 Apr; 53(2):186-7. PubMed ID: 9689806
[TBL] [Abstract][Full Text] [Related]
24. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
25. Nucleolar organizer regions distribution in fine needle aspiration cytological smears from breast lesions.
Hasnan J; Jayaram G
Malays J Pathol; 1996 Jun; 18(1):35-41. PubMed ID: 10879223
[TBL] [Abstract][Full Text] [Related]
26. Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma.
Marchevsky AM; Wick MR
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):140-4. PubMed ID: 17525624
[TBL] [Abstract][Full Text] [Related]
27. Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis.
Cappello F; Barnes L
Pathology; 2001 May; 33(2):142-8. PubMed ID: 11358044
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of AgNOR count in distinguishing benign from malignant mesothelial cells in pleural fluids.
Colecchia M; Leopardi O
Pathol Res Pract; 1992 Jun; 188(4-5):541-4. PubMed ID: 1409085
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
Shen J; Pinkus GS; Deshpande V; Cibas ES
Am J Clin Pathol; 2009 Apr; 131(4):516-23. PubMed ID: 19289587
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic relevance of silver stained nucleolar organizer region (AgNORs) in benign and malignant breast lesions.
Agarwal PK; Mehrotra A; Chandra T
Indian J Exp Biol; 1995 Oct; 33(10):715-20. PubMed ID: 8575800
[TBL] [Abstract][Full Text] [Related]
33. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
Saad RS; Cho P; Liu YL; Silverman JF
Diagn Cytopathol; 2005 Mar; 32(3):156-9. PubMed ID: 15690334
[TBL] [Abstract][Full Text] [Related]
34. Markers for the non-invasive diagnosis of mesothelioma: a systematic review.
van der Bij S; Schaake E; Koffijberg H; Burgers JA; de Mol BA; Moons KG
Br J Cancer; 2011 Apr; 104(8):1325-33. PubMed ID: 21448170
[TBL] [Abstract][Full Text] [Related]
35. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
Brockstedt U; Gulyas M; Dobra K; Dejmek A; Hjerpe A
Am J Clin Pathol; 2000 Aug; 114(2):203-9. PubMed ID: 10941335
[TBL] [Abstract][Full Text] [Related]
36. What is the best way to diagnose and stage malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
[TBL] [Abstract][Full Text] [Related]
37. [Usefulness of AgNOR technique in the interpretation of serous effusions].
Rocher AE; Blanco AM; Palaoro LA
Rev Med Chil; 2000 Sep; 128(9):963-8. PubMed ID: 11349500
[TBL] [Abstract][Full Text] [Related]
38. p27 immunostaining is related to prognosis in malignant mesothelioma.
Beer TW; Shepherd P; Pullinger NC
Histopathology; 2001 Jun; 38(6):535-41. PubMed ID: 11422497
[TBL] [Abstract][Full Text] [Related]
39. [Surfactant protein and thyroid transcription factor 1 in pleuro-pulmonary neoplasia. Immunohistochemical study].
Dessy E; Falleni M; Del Curto B; Braidotti P; Pietra GG
Pathologica; 2000 Dec; 92(6):496-502. PubMed ID: 11234300
[TBL] [Abstract][Full Text] [Related]
40. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
